Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma Jan 04, 2023
Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29 Dec 20, 2022
Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones Dec 19, 2022
Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Dec 15, 2022
Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa Dec 14, 2022
Fortress Biotech to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference Dec 06, 2022
Journey Medical Corporation to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference Dec 05, 2022
Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights Nov 14, 2022
